

IL17A, IL17F

Research Grade Afasevikumab

Catalog No.	DHH28807A DHH28807B	Quantity:	100 µg 1.0 mg
Alternate Names:	Interleukin-17A, IL-17A, CTLA-8, Interleukin-17F, IL-17F, MCAF-5352A, MCAF5352A, NI-1401, RG-7624, RG7624, RO5553110		
Description:	Afasevikumab is a human monoclonal antibody that targets IL17A and IL-17F.		
Concentration:	1.0 mg/ml, lot specific		
UniProt ID (target):	Q16552, Q96PD4		
Source:	XtenCHO cell line		
Isotype:	Human IgG1 kappa		
INN:	Afasevikumab		
Specificity:	Human IL-17A, IL-17F		
Endotoxin:	≤ 0.01 EU/µg by LAL analysis		
Formulation:	0.01M PBS, pH 7.4		
Purification:	Protein A/G affinity chromatography		
Purity:	> 95% as determined by SDS-PAGE		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.